InSyBio
Narragansett
About InSyBio
InSyBio is a biotechnology pioneer company (www.insybio.com) in personalized healthcare and nutrition which focuses on developing computational frameworks and tools for the analysis of complex life-science and biological data. The key objective of our analysis lies in discovering predictive integrated biosignatures (biomarkers of various categories) and models with increased prognostic and diagnostic aspects for personalized Healthcare and Nutrition Industries. Our key products include: -A SaaS platform, InSyBio Suite, for facilitating analysis of biomedical multi-omics data, reducing by 80% time and resources needs for such analysis and raising accuracy of predictive models by at least 10%. -InSyBio Personalization Test which is a tailor-made product for each nutrition company allowing the personalization of nutrition, nutraceutical, vitamin and probiotic products. Since June 2015 InSyBio participates in NBG Business Seeds program by National Bank of Greece and since 2021 InSyBio participates in the Loyal VC program. For more information about our company contact us at [email protected].
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $550.0K
- Funding stage: Early Stage Venture
- Last round: Series A (Jul 2023)
- Website: insybio.com
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Bioinformatics, Biotechnology, Machine Learning, Nutrition
Social Profiles
Canonical: https://fsome.com/organization/insybio-15201 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.